"PROSPECTIVE, RANDOMIZED, OPEN LABEL CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DEXMEDETOMIDINE USE BEYOND 24 HOURS COMPARED WITH MIDAZOLAM IN CHILDREN ADMITTED TO PEDIATRIC INTENSIVE CARE UNIT (PICU) AT KASCH-MNGHA. (PROMISE)"

drug protocol number
RC20/160/R
drug sponsor
KAIMRC
drug study
Dexmedetomidine (Hospira)
drug trial site
King Abdulaziz Medical City NG (Riyadh)
drug status
Rejected
drug phase